Recent Updates
Recently added Catalysts
KRRO Positive Sentiment

Korro to Participate in Upcoming Investor Conferences

Key Takeaway: Korro Bio, Inc. announced its participation in three upcoming investor conferences. CEO Ram Aiyar will engage in discussions at the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and the Piper Sandler Healthcare Conference. The company is focused on advancing its OPERA platform for developing genetic medicines targeting rare diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Korro is participating in multiple investor conferences.
  • The OPERA platform offers innovative RNA-editing capabilities.
  • Korro aims to develop genetic medicines for rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+163%
120-day peak, hindsight
Typical move
44.6%
average across 2 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
KRRO-121
Phase 2 · Urea Cycle Disorders, Inborn

Full Press Release Details

CAMBRIDGE, Mass., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in the following investor conferences:
9th Annual Evercore Healthcare Conference Format: Fireside chat moderated by Jonathan Miller, Biotech and Pharma Equity Research, Evercore Date: December 1, 2026 Location: Miami, FL Time: 7:55AM ET

Citi’s 2026 Global Healthcare Conference Format: One-on-one Meetings Date: December 2, 2026 Location: Miami, FL

Piper Sandler 38th Annual Healthcare Conference Format: Fireside chat moderated by Yasmeen Rahimi, Ph.D., Senior Research Analyst at Piper Sandler Date: December 3, 2026 Location: New York, NY Time: 1:00PM ET

About Korro

Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Korro Bio Contact Information

Investor & Media Contact Malini Chatterjee, Ph.D Blueprint Life Science Group mchatterjee@bplifescience.com or ir@korrobio.com 917.330.4269

Frequently Asked Questions

Who is participating in the investor conferences?

Korro's CEO, Ram Aiyar, will participate in the conferences.

What is the OPERA platform?

The OPERA platform is used for RNA-editing to develop genetic medicines.

When are the investor conferences scheduled?

The conferences are scheduled for December 1-3, 2026.

Where will the conferences take place?

The conferences will be held in Miami, FL, and New York, NY.

Last updated: Nov 19, 2026